A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer (OTT10-06)

Ottawa Hospital Research Institute

Status and phase: Terminated; Phase 2

Conditions: Prostatic Neoplasms

Treatments: Drug: Degarelix

Study type: Interventional

Funder types: Other

Identifiers

NCT01545882

OTT10-06 (Other Identifier)

10-059

Details and patient eligibility

About

This study is being offered to patients who have hormone resistant prostate cancer (HRPC). This means that their prostate cancer is no longer responding to standard hormonal therapy.

The purpose of this study is to determine whether Degarelix will be able to stop the PSA from rising in patients with hormone resistant prostate cancer.

Full description

This is a phase II study of a GnRH antagonist drug, Degarelix, for use in hormone resistant prostate cancer patients who have had biochemical PSA progression despite the use of total androgen blockade therapy. Patients will receive at least six monthly injections of Degarelix unless the patient shows radiographic or symptomatic disease progression, intolerable toxicity or decides to withdraw from the study. Patients will be evaluated for measures of efficacy, toxicity and disease progression during treatment and afterwards until radiologically confirmed metastatic disease progression or until the patient is removed from the study.

Overall objective:

The efficacy of Degarelix as a treatment for HRPC will be evaluated

Enrollment: 5 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prior trial of total androgen blockade
• Confirmed biochemical PSA progression on agonist therapy, defined as ≥ 50% increase in PSA between 2 measurements, taken at least 1 week apart. In patients that are currently on total androgen blockade (LHRH agonist plus non-steroidal anti-androgen) there must be a trial withdrawal of androgen receptor antagonists to ensure that there is no PSA response (6 weeks for bicalutamide and 4 weeks for flutamide or nilutamide).
• Radiologically confirmed non-metastatic disease within 90 days of registration based on negative chest radiographs, CT Scan Abdomen/Pelvis and Bone scan
• ECOG ≤ 2
• Age ≥ 18 years
• Serum testosterone of ≤ 50 mg/dl
• PSA ≥ 2.0 ng/ml
• White blood cell count ≥ 3000/mm3
• Platelets ≥ 100,000/mm3
• Serum creatinine ≤ 1.5 x upper limits of normal
• Bilirubin ≤ 1.5 x upper limits of normal
• Alanine transaminase ≤ 1.25 x upper limits of normal
• Estimated life expectancy of at least 12 months
• Able and willing to sign informed consent

Exclusion criteria

• Prior treatment with chemotherapy, radiopharmaceuticals, estrogen, PC-SPES, ketoconazole or other second line hormonal therapy (other than non-steroidal anti-androgens or Androcur)
• Known allergy to GnRH agonists or antagonists
• Previous treatment with Degarelix
• Major surgery within 4 weeks of registration
• Grade ≥ 3 peripheral neuropathy
• Severe, active co-morbidity such as unstable angina, congestive heart failure or myocardial infarction within the last 6 months or congenital long QT syndrome
• Acute deep vein thrombosis or pulmonary embolism
• Taking anti-arrhythmia medication
• Second malignancy other than non-melanoma skin cancer unless disease free ≥ 5 years.
• Prior orchiectomy for prostate cancer
• PSA > 100 ng/mL

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

5 participants in 1 patient group

Degarelix

Experimental group

Description:

Degarelix treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.

Treatment:

Drug: Degarelix